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Summary
Non-immune fetal hydrops is diagnosed when there is
fluid accumulation in more than one extravascular
space. A long list of etiologies has been found in asso-
ciation with non-immune hydrops. Thorough investiga-
tions are needed to be able to identify an underlying
cause. There are many recent reports indicating that
non-immune hydrops can be an extreme presentation
of a number of metabolic disorders, mostly lysosomal
storage diseases. The fetal hydrops associated with
metabolic disorders is usually severe with very thick
skin, massive ascitis, other feature could be seen such
as contracture deformities, skeletal abnormalities, he-
patosplenomegaly, renal abnormalities, and enlarged
nuchal translucency. The diagnosis of a metabolic dis-
order can be done by a variety of different tests: meas-
uring the level of the specific enzyme or metabolite,
histological examination of different organs, or muta-
tion identification. An index case is usually needed to
confirm the diagnosis. In-utero diagnosis of a metabol-
ic disorder in the absence of an index case is difficult
and only available in selected laboratories around the
world. In populations with high consanguinity, these
diseases are much more commonly present than what
we might think. Routine screening for metabolic dis-
eases especially lysosomal storage diseases should be
considered in these populations, and definitely in cas-
es of recurrent hydrops in the same family. More efforts
should be spent on identifying causative mutations in
different ethnic groups. Every effort should be made to
identify the etiology in an index case in the family, as
this might be the best opportunity for improving future
care.  
Introduction
Non-immune fetal hydrops is a condition easily diag-
nosed by antenatal ultrasound. The diagnosis is
reached when there is fluid accumulation in more than
one extravascular space, this includes soft tissue ede-
ma in the skin or scalp, or fluid in body cavities such as
ascites pleural effusion, pericardial effusion, or hydro-
cele. Non-immune fetal hydrops is a clinical phenotype
and not a diagnosis. It is associated with a broad spec-
trum of causes. The identification of hydrops by ultra-
sound is very frustrating to the family and physicians be-
cause it requires extensive search for the etiology, which
include a wide variety of diseases and pathologies.
Even after undergoing a long list of testing, a good num-
ber of cases remain with no clear diagnosis. In addition,  
the prognosis has  traditionally  been reported as  poor with
perinatal loss of 70-90% (1,2), more recent studies whe-
re  more  extensive work-up and in-utero treatment  were
utilized, better perinatal outcome was reported (3, 4). 
Etiology of non-immune hydrops
A long list of etiologies has been found to be associated
with non-immune hydrops. This includes fetal, maternal
and placental/cord abnormalities. In previous reports,
there were a large number of cases labeled as idiopath-
ic. More recently, investigators have shown that with
thorough investigations, an underlying cause can be
identified in up to 84% of such fetuses. When hydrops
fetalis is followed by intrauterine fetal death, the success
rate for identifying an etiology for the hydrops drops to
40% (5).
Fetal causes include cardiac defects either structural
defects such as (but not limited to) hypoplastic left or
right heart, artiroventricular septal defects, aortic steno-
sis or atresia, pulmonary stenosis or atresia, tetralogy of
Fallot, premature closure of the ductus, or arrhythmias
such as supraventricular tachycardia, atrial flutter, or
heart block. Chromosomal abnormalities, skeletal dys-
plasia, feto-maternal hemorrhage and hematologic ab-
normalities are also important causes. Some structural
fetal defects are associated with hydrops such as di-
aphragmatic hernia, intestinal or esophageal atresias,
polycystic kidneys, bronchopulmonary sequestration,
and congenital cystic adenomatoid malformation. Some
fetal tumors can be associated with or can lead to hy-
drops, examples are neuroblastoma and sacrococ-
cygeal teratoma. There are a number of genetic syn-
dromes presenting with fetal hydrops including multiple
pterygium, Noonan syndrome, Cornelia de Lange,
tuberous sclerosis, myotonic dystrophy and Neu-Laxova
syndrome.
Maternal disease include severe maternal anemia, dia-
betes and maternal indomethacin use. Placental/cord
pathology include: chorioangioma, angiomyxoma of the
cord, and chorionic vein thrombosis. 
Metabolic disorders have been traditionally included in
this long list, but as these diseases are very rare, routine
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testing has not been part of the work-up list for non-im-
mune hydrops.
Metabolic disorders as a cause of non-immune 
hydrops
It has been recognized that a number of cases of non-im-
mune hydrops were found to be secondary to lysosomal
storage diseases and other metabolic disorders (6, 7).
This include mucopolysacccharidosis type VII (Sly dis-
ease) and IVA (Morquio A syndrome), Gaucher disease
type 2, sialidosis, GM1 gangliosidosis, galactosialidosis,
Niemann-Pick disease type C, disseminated lipogranulo-
matosis (Farber disease), infantile free sialic acid storage
(ISSD), and mucolipidosis II (I-cell disease). 
There are many reports coming up in the literature indi-
cating that non-immune hydrops can be an extreme
presentation of a number of metabolic disorders, usual-
ly recurrent in the same family (8-11). Most of the recent
reports are reporting antenatal ultrasound findings and
prenatal or postnatal diagnosis. The association of lyso-
somal storage diseases with hydrops is not new phe-
nomena, the pediatrics literature has reported this asso-
ciation in the postnatal period many years earlier (12).
Although lysosomal storage diseases are rare disor-
ders, the combined incidence is around 1 in 1,500 births
(13), with clear ethnic variations. Consanguinity is an im-
portant contributor to the increase risk for these disor-
ders in these ethnic groups.
Diagnosis of a metabolic disorder in cases 
of non-immune hydrops
To reach a diagnosis for the underlying cause of a meta-
bolic disease for non-immune hydrops, a high index of
suspicion is required. The risk is higher if the hydrops is
recurrent for the same couple, or if a family history is
positive for a metabolic disease or non-immune hy-
drops. 
Ultrasound can give a clue for the suspicion. The fetal hy-
drops associated with metabolic disorders is usually se-
vere hydrops with massive ascites, and very thick skin.
Other feature includes course faces (which might be diffi-
cult to see with the massive skin edema), contracture de-
formities, skeletal abnormalities, hepatosplenomegaly (5,
14), and renal abnormalities. 
The diagnosis of a metabolic disorder can be done by a
variety of different tests. The classic diagnosis is usual-
ly done by measuring the level of the specific enzyme.
Different lysosomal storage diseases are associated
with different enzyme deficiency. Examples include be-
ta-glucuronidase deficiency in Mucopolysaccharidosis
type VII, beta-galactosidase deficiency in GM1 gan-
gliosidosis.
Other methods of diagnosis include histological exami-
nation of different organs such as liver, spleen, lungs,
bone marrow, or placenta (15, 16). Mutation identifica-
tion is not available for all diseases, and in some dis-
eases the parents might not be carrying the common
mutation for that particular disorder, which could limit the 
possibility of prenatal diagnosis (17).
Another difficulty that is faced in some diseases is that
there are cases of pseudodeficiency in the enzyme
which might be common in a particular disease (exam-
ple include metachromatic leucodystrophy). In these
cases it is important to know the enzyme level in the par-
ents and the index case, or the mutation in the family be-
fore prenatal diagnosis can be offered (18). Because of
these issues, In-utero diagnosis of a metabolic disorder
in the absence of an index case is difficult and only
available in selected laboratories around the world.
Few numbers of cases of Mucopolysaccharidosis type
VII have been reported with prenatal diagnosis, by either
amniocentesis or chorionic villus sampling, most of
which there was a previously affected child in the family
(10, 19, 20).
It is therefore of ultimate importance to try to identify the
cause of non-immune hydrops in the index case, if not
antenatal, then postnatal. This will be helpful when deal-
ing with these families preconception, in order to provide
them with appropriate counseling and options for next
pregnancy. 
Screening for metabolic abnormalities should be consid-
ered in any work-up for non-immune hydrops fetalis, but
with repeat hydrops it should be mandatory.
Large nuchal translucency and metabolic disorders
Nuchal translucency, which is a measurement of the flu-
id accumulation in the back of the fetal neck has been
found to be increased not only in fetuses with chromo-
somal abnormalities, but also in a variety of fetal abnor-
malities including structural fetal defects and genetic
diseases (21). Since that time, many reports came out
to indicate that metabolic disorders can be suspected if
increased nuchal translucency is diagnosed in the first
trimester. Many metabolic diseases have been found to
have this association including Zellweger syndrome (22-
24), mucopolysaccharidosis type VII (25, 26). Obvious-
ly, not all lysosomal storage diseases present with en-
larged nuchal translucency, a recent study by De Biasio
et al demonstrated that nuchal translucency could be
normal in these fetuses (27).  
Conclusions
Metabolic disorders, although uncommon, must be al-
ways thought of when investigating cases of non-im-
mune hydrops, and enlarged nuchal translucency. De-
pending on the population managed, these diseases are
much more commonly present than what we might think.
Routine screening for metabolic diseases especially
lysosomal storage diseases should be considered in at
risk population, and definitely in cases of recurrent hy-
drops in the same family. More efforts should be spent
on identifying causative mutations in different ethnic
groups. Every effort should be made to identify the etiol-
ogy in an index case in the family as this might be the
best opportunity for improving future care. 
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